Competing interests
Breast Cancer
ONCOLOGY, BREAST CANCER
Hiroji Iwata: Consulting fees: Daichi Sankyo, Chugai, AstraZeneca, Sanofi, Lilly, MSD, Pfizer, and Novartis; Honoraria: Daiichi Sankyo, Chugai, AstraZeneca, Lilly, MSD, and Pfizer; Advisory Board: Daichi Sankyo, Chugai, AstraZeneca, Sanofi, Lilly, MSD, Pfizer, and Novartis. Yutaka Yamamoto: Research Funding: MSD Oncology, Chugai, Eisai, Daiichi Sankyo, Nippon Kayaku, Taiho, AstraZeneca, Takeda, and Pfizer; Honoraria: AstraZeneca, Chugai, Kyowa Kirin, Novartis, Lilly Japan, Pfizer, Daiichi Sankyo, MSD, Taiho, Eisai, Takeda, and Sysmex; Advisory Board: AstraZeneca, Chugai, Novartis, Lilly, Pfizer, Daiichi Sankyo, and MSD; Member of the Board of Directors: Japanese Breast Cancer Society and Japan Breast Cancer Research Group. Shoichiro Ohtani: Honoraria: Chugai, Lilly, Pfizer, AstraZeneca, and Eisai. Masahiro Kashiwaba: Honoraria: Chugai, Kyowa Kirin, Lilly Japan, Shionogi, Taiho, Daiichi Sankyo, Eisai, AstraZeneca, Pfizer, and Novartis. Naruto Taira: Honoraria: Pfizer, AstraZeneca, Eisai, ACTmed, and Kyowa Kirin. Tatsuya Toyama: Honoraria: Chugai, Eisai, Novartis, Takeda, Nippon Kayaku, AstraZeneca, Pfizer, and Lilly. Norikazu Masuda: Research Funding: Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa Kirin, and Nippon Kayaku; Honoraria: Eisai, Novartis, Sanofi, Kyowa Kirin, and Nippon Kayaku; Executive Board: Japan Breast Cancer Research Group; Board of Directors: Japanese Breast Cancer Society. Takuhiro Yamaguchi: Research Funding: Kyowa Kirin, AC Medical, A2 Healthcare, Facet Biotech, Japan Tobacco, Japan Media, Medidata Solutions, Ono, Intellim Corporation, Welby, 3H Medi Solution, Nipro, Hemp Kitchen, Nobori, Puravida Technologies, Medrio, 3H Clinical Trial, Senju Pharmaceutical, Otsuka, Eisai, and ClinChoice; Consulting or Advisory Role: EP Croit, Japan Tobacco, Ono, Kowa Company, Daiichi Sanko, Eisai, Chugai, 3H Clinical Trial, Sonire Therapeutics, Seikagaku Corporation, Otsuka, and Incyte Biosciences; Stock and Other Ownership Interests: STATCOM; Speakers' Bureau: Daiichi Sankyo, Takeda, Mebix, and AstraZeneca. Other authors have nothing to disclose.